Roche: Exit Equities, Enter Drugs
Executive Summary
It's the end of an era for Roche. Long known for its black-box financial dealings, the Swiss group has shut down investment arm Roche Finance and declared a renewed focus on its Pharma and Diagnostics businesses. The bold bid for transparency hasn't come cheap, but it's timely. Transparency is all the rage, and for the first time in years, Roche has something in its pipeline to point to.